Literature DB >> 10411465

Functionalized congeners of 1,4-dihydropyridines as antagonist molecular probes for A3 adenosine receptors.

A H Li1, L Chang, X d Ji, N Melman, K A Jacobson.   

Abstract

4-Phenylethynyl-6-phenyl-1,4-dihydropyridine derivatives are selective antagonists at human A3 adenosine receptors, with Ki values in a radioligand binding assay vs [125I]AB-MECA [N(6)-(4-amino-3-iodobenzyl)-5'-N-methylcarbamoyl-adenosine] in the submicromolar range. In this study, functionalized congeners of 1,4-dihydropyridines were designed as chemically reactive adenosine A3 antagonists, for the purpose of synthesizing molecular probes for this receptor subtype. Selectivity of the new analogues for cloned human A3 adenosine receptors was determined in radioligand binding in comparison to binding at rat brain A1 and A2A receptors. Benzyl ester groups at the 3- and/or 5-positions and phenyl groups at the 2- and/or 6-positions were introduced as potential sites for chain attachment. Structure-activity analysis at A3 adenosine receptors indicated that 3,5-dibenzyl esters, but not 2,6-diphenyl groups, are tolerated in binding. Ring substitution of the 5-benzyl ester with a 4-fluorosulfonyl group provided enhanced A3 receptor affinity resulting in a Ki value of 2.42 nM; however, a long-chain derivative containing terminal amine functionalization at the 4-position of the 5-benzyl ester showed only moderate affinity. This sulfonyl fluoride derivative appeared to bind irreversibly to the human A3 receptor (1 h incubation at 100 nM resulting in the loss of 56% of the specific radioligand binding sites), while the binding of other potent dihydropyridines and other antagonists was generally reversible. At the 3-position of the dihydropyridine ring, an amine-functionalized chain attached at the 4-position of a benzyl ester provided higher A3 receptor affinity than the corresponding 5-position isomer. This amine congener was also used as an intermediate in the synthesis of a biotin conjugate, which bound to A3 receptors with a Ki value of 0.60 microM.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411465      PMCID: PMC3446815          DOI: 10.1021/bc9900136

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  30 in total

1.  Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists.

Authors:  Y Karton; J L Jiang; X D Ji; N Melman; M E Olah; G L Stiles; K A Jacobson
Journal:  J Med Chem       Date:  1996-06-07       Impact factor: 7.446

2.  Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors.

Authors:  J Strickler; K A Jacobson; B T Liang
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

3.  Characterization of adenosine receptors in rat brain by (-)[3H]N6-phenylisopropyladenosine.

Authors:  U Schwabe; T Trost
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-09       Impact factor: 3.000

4.  Persistent activation by and receptor reserve for an irreversible A1-adenosine receptor agonist in DDT1 MF-2 cells and in guinea pig heart.

Authors:  J Zhang; L Belardinelli; K A Jacobson; D H Otero; S P Baker
Journal:  Mol Pharmacol       Date:  1997-09       Impact factor: 4.436

5.  A novel cardioprotective function of adenosine A1 and A3 receptors during prolonged simulated ischemia.

Authors:  K Stambaugh; K A Jacobson; J L Jiang; B T Liang
Journal:  Am J Physiol       Date:  1997-07

6.  Molecular cloning and characterization of the human A3 adenosine receptor.

Authors:  C A Salvatore; M A Jacobson; H E Taylor; J Linden; R G Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

7.  Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor.

Authors:  Q Y Zhou; C Li; M E Olah; R A Johnson; G L Stiles; O Civelli
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

8.  Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects.

Authors:  D K Von Lubitz; R C Lin; M Boyd; N Bischofberger; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1999-02-19       Impact factor: 4.432

9.  Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate.

Authors:  B Fischer; J L Boyer; C H Hoyle; A U Ziganshin; A L Brizzolara; G E Knight; J Zimmet; G Burnstock; T K Harden; K A Jacobson
Journal:  J Med Chem       Date:  1993-11-26       Impact factor: 7.446

10.  Functionalized congeners of 1,3-dialkylxanthines: preparation of analogues with high affinity for adenosine receptors.

Authors:  K A Jacobson; K L Kirk; W L Padgett; J W Daly
Journal:  J Med Chem       Date:  1985-09       Impact factor: 7.446

View more
  6 in total

1.  Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system.

Authors:  Dilip K Tosh; Moshe Chinn; Andrei A Ivanov; Athena M Klutz; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

2.  Synthesis, pharmacological evaluation and molecular docking of pyranopyrazole-linked 1,4-dihydropyridines as potent positive inotropes.

Authors:  Rakesh Kumar; Neha Yadav; Rodolfo Lavilla; Daniel Blasi; Jordi Quintana; José Manuel Brea; María Isabel Loza; Jordi Mestres; Mamta Bhandari; Ritu Arora; Rita Kakkar; Ashok K Prasad
Journal:  Mol Divers       Date:  2017-04-25       Impact factor: 2.943

Review 3.  Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs).

Authors:  Kenneth A Jacobson
Journal:  Bioconjug Chem       Date:  2009-04-30       Impact factor: 4.774

Review 4.  Molecular probes for the human adenosine receptors.

Authors:  Xue Yang; Laura H Heitman; Adriaan P IJzerman; Daan van der Es
Journal:  Purinergic Signal       Date:  2020-12-12       Impact factor: 3.765

Review 5.  International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.

Authors:  Adriaan P IJzerman; Kenneth A Jacobson; Christa E Müller; Bruce N Cronstein; Rodrigo A Cunha
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

6.  Enhanced A3 adenosine receptor selectivity of multivalent nucleoside-dendrimer conjugates.

Authors:  Athena M Klutz; Zhan-Guo Gao; John Lloyd; Asher Shainberg; Kenneth A Jacobson
Journal:  J Nanobiotechnology       Date:  2008-10-23       Impact factor: 10.435

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.